We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
06 Aug 2020 - 08 Aug 2020

Interatrial Shunt Helps Decompress Failing Heart

By HospiMedica International staff writers
Posted on 24 Oct 2019
Print article
Image: The Corvia InterAtrial Shunt Device (IASD) (Photo courtesy of Corvia Medical).
Image: The Corvia InterAtrial Shunt Device (IASD) (Photo courtesy of Corvia Medical).
A novel implantable cardiac shunt helps treat heart failure (HF) patients with preserved and mid-range ejection fraction.

The Corvia Medical (Tewksbury, MA, USA) Interatrial Shunt Device (IASD) is an innovative transcatheter implantable device designed to help diastolic HF function by forming a channel that connects left and right atria, thus facilitating continuous and dynamic decompression of the left atrium and enabling it to relax at rest and physical activity. Once in place, a permanent passage is created in the septum between the atria, resulting in reduction in HF symptoms, improved quality of life, and reduced hospitalization rates.

The IASD, which has been granted “Breakthrough Device” designation by the U.S. Food and Drug Administration (FDA), is being studied in the REDUCE LAP-HF II study, a large multi-national prospective, double-blind, sham-controlled trial randomizing 608 HFpEF and HFmrEF patients in the United States, European Union, Australia, Japan, and Canada. One-year follow-up data of the IASD clinical study, held in 64 patients implanted at 18 centers, demonstrated shunt patency for all participants who received the implant.

“Receiving Breakthrough Device designation from the FDA underscores the significant unmet need for more effective treatment options for heart failure patients,” said George Fazio, President and CEO of Corvia Medical. “We look forward to continuing our work with the FDA through our ongoing pivotal trial in more than 100 hospitals, and providing the clinical evidence which will accelerate the timeline to bring the IASD to the U.S. market.”

There are two types of HF; HF with reduced ejection fraction (HFrEF, systolic heart failure), and heart failure with preserved or mid‐range ejection fraction (HFpEF/HFmrEF), previously called diastolic heart failure. HFpEF accounts for approximately 50% of all HF, but treatment options are limited, consisting mainly of diuretics and fluid balance control. Although the pathophysiology of HFpEF is complex, many of the symptoms are a result of excessive rises in left atrial pressure, in particular during exercise.

Related Links:
Corvia Medical

Print article



view channel

Siemens to Acquire Varian Medical to Create Comprehensive Cancer Portfolio

Siemens Healthineers (Erlangen, Germany) has entered into an agreement to acquire Varian Medical Systems, Inc. (Palo Alto, CA, USA) that will lead to the creation of a global leader in healthcare with... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.